Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

bavarian nordic berna gmbh - toxoidum diphtheriae, toxoidum tetani - injektionssuspension - toxoidum diphtheriae min. 2 u.i., toxoidum tetani min. 40 u.i., adjuvans: aluminium max. 1.25 mg ut aluminii phosphatis liquamen, natrii chloridum, natrii acetas trihydricus, natrii carbonas, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml corresp. natrium 2.07 mg. - impfstoffe

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

mylan pharma gmbh - haemagglutininum influenzae a (h1n1) (virus-stamm a/victoria/2570/2019 (h1n1)-pdm09: reassortant virus ivr-215 derived from a/victoria/2570/2019), haemagglutininum influenzae a (h3n2) (virus-stamm a/cambodia/e0826360/2020 (h3n2)-like: reassortant virus ivr-224 derived from a/cambodia/e0826360/2020), haemagglutininum influenzae b (virus-stamm b/washington/02/2019 (victoria lineage)) - injektionssuspension - haemagglutininum influenzae a (h1n1) (virus-stamm a/victoria/2570/2019 (h1n1)-pdm09: reassortant virus ivr-215 derived from a/victoria/2570/2019) 15 µg, haemagglutininum influenzae a (h3n2) (virus-stamm a/cambodia/e0826360/2020 (h3n2)-like: reassortant virus ivr-224 derived from a/cambodia/e0826360/2020) 15 µg, haemagglutininum influenzae b (virus-stamm b/washington/02/2019 (victoria lineage)) 15 µg, haemagglutininum influenzae b (virus-stamm b/phuket/3073/2013 (yamagata lineage)) 15 µg, kalii chloridum, kalii dihydrogenophosphas, dinatrii phosphas dihydricus, natrii chloridum, calcii chloridum dihydricum, magnesii chloridum hexahydricum, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml corresp. natrium 2.0 mg, kalium 0.1 mg, residui: cetrimidum, formaldehydum, gentamicini sulfas, polysorbatum 80, ovalbuminum. - aktive immunisierung gegen influenza, ab 6 monaten - impfstoffe

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

viatris pharma gmbh - haemagglutininum influenzae a (h1n1) (virus-stamm a/victoria/2570/2019 (h1n1)-pdm09: reassortant virus ivr-215 derived from a/victoria/2570/2019), haemagglutininum influenzae a (h3n2) (virus-stamm a/darwin/9/2021 (h3n2)-like: reassortant virus derived from a/darwin/9/2021, san-010), haemagglutininum influenzae b (virus-stamm b/austria/1359417/2021 -like: reassortant virus bvr-26 derived from b/austria/1359417/2021 (victoria lineage)) - injektionssuspension - haemagglutininum influenzae a (h1n1) (virus-stamm a/victoria/2570/2019 (h1n1)-pdm09: reassortant virus ivr-215 derived from a/victoria/2570/2019) 15 µg, haemagglutininum influenzae a (h3n2) (virus-stamm a/darwin/9/2021 (h3n2)-like: reassortant virus derived from a/darwin/9/2021, san-010) 15 µg, haemagglutininum influenzae b (virus-stamm b/austria/1359417/2021 -like: reassortant virus bvr-26 derived from b/austria/1359417/2021 (victoria lineage)) 15 µg, haemagglutininum influenzae b (virus-stamm b/phuket/3073/2013 (yamagata lineage)) 15 µg, kalii chloridum, kalii dihydrogenophosphas, dinatrii phosphas dihydricus, natrii chloridum, calcii chloridum dihydricum, magnesii chloridum hexahydricum, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml corresp. natrium 2.0 mg, kalium 0.1 mg, residui: cetrimidum, formaldehydum, gentamicini sulfas, polysorbatum 80, ovalbuminum. - aktive immunisierung gegen influenza, ab 6 monaten - impfstoffe

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

msd merck sharp & dohme ag - polysaccharida streptococci pneumoniae typus 1 conjugata cum proteino corynebacteriae diphtheriae crm 197, polysaccharida streptococci pneumoniae typus 3 conjugata cum proteino corynebacteriae diphtheriae crm 197, polysaccharida streptococci pneumoniae typus 4 conjugata cum proteino corynebacteriae diphtheriae crm 197, polysaccharida streptococci pneumoniae typus 5 conjugata cum proteino corynebacteriae diphtheriae crm 197, polysaccharida streptococci pneumoniae typus 6a conjugata cum proteino corynebacteriae diphtheriae crm 197, polysaccharida streptococci pneumoniae typus 6b conjugata cum proteino corynebacteriae diphtheriae crm 197, polysaccharida streptococci pneumoniae typus 7f conjugata cum proteino corynebacteriae diphtheriae crm 197, polysaccharida streptococci pneumoniae typus 9v conjugata cum proteino corynebacteriae diphtheriae crm 197, polysaccharida streptococci pneumoniae typus 14 conjugata cum proteino corynebacteriae diphtheriae crm 197, polysaccharida streptococci pneumoniae typus 18c conjugata cum proteino corynebacteriae diphtheriae crm 197, polysaccharida streptococci pneumoniae typus 19a conjugata cum proteino corynebacteriae diphtheriae crm 197, polysaccharida streptococci pneumoniae typus 19f conjugata cum proteino corynebacteriae diphtheriae crm 197, polysaccharida streptococci pneumoniae typus 22f conjugata cum proteino corynebacteriae diphtheriae crm 197, polysaccharida streptococci pneumoniae typus 23f conjugata cum proteino corynebacteriae diphtheriae crm 197, polysaccharida streptococci pneumoniae typus 33f conjugata cum proteino corynebacteriae diphtheriae crm 197 - injektionssuspension - polysaccharida streptococci pneumoniae typus 1 conjugata cum proteino corynebacteriae diphtheriae crm 197 2 µg et polysaccharida streptococci pneumoniae typus 3 conjugata cum proteino corynebacteriae diphtheriae crm 197 2 µg et polysaccharida streptococci pneumoniae typus 4 conjugata cum proteino corynebacteriae diphtheriae crm 197 2 µg et polysaccharida streptococci pneumoniae typus 5 conjugata cum proteino corynebacteriae diphtheriae crm 197 2 µg et polysaccharida streptococci pneumoniae typus 6a conjugata cum proteino corynebacteriae diphtheriae crm 197 2 µg et polysaccharida streptococci pneumoniae typus 6b conjugata cum proteino corynebacteriae diphtheriae crm 197 4 µg et polysaccharida streptococci pneumoniae typus 7f conjugata cum proteino corynebacteriae diphtheriae crm 197 2 µg et polysaccharida streptococci pneumoniae typus 9v conjugata cum proteino corynebacteriae diphtheriae crm 197 2 µg et polysaccharida streptococci pneumoniae typus 14 conjugata cum proteino corynebacteriae diphtheriae crm 197 2 µg et polysaccharida streptococci pneumoniae typus 18c conjugata cum proteino corynebacteriae diphtheriae crm 197 2 µg et polysaccharida streptococci pneumoniae typus 19a conjugata cum proteino corynebacteriae diphtheriae crm 197 2 µg et polysaccharida streptococci pneumoniae typus 19f conjugata cum proteino corynebacteriae diphtheriae crm 197 2 µg et polysaccharida streptococci pneumoniae typus 22f conjugata cum proteino corynebacteriae diphtheriae crm 197 2 µg et polysaccharida streptococci pneumoniae typus 23f conjugata cum proteino corynebacteriae diphtheriae crm 197 2 µg et polysaccharida streptococci pneumoniae typus 33f conjugata cum proteino corynebacteriae diphtheriae crm 197 2 µg corresp. polysaccharida 32 µg et proteinum corynebacteriae diphtheriae crm 197 ca. 30 µg, adjuvans: aluminium 0.125 mg ut aluminii phosphas, natrii chloridum corresp. natrium 1.77 mg, histidinum, polysorbatum 20, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml. - aktive immunisierung gegen pneumokokken-infektionen der serotypen 1, 3, 4, 5, 6a, 6b, 7f, 9v, 14, 18c, 19a, 19f, 22f, 23f, 33f - impfstoffe

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - toxoidum diphtheriae, toxoidum tetani, toxoidum pertussis, haemagglutininum filamentosum (b. pertussis), pertactinum (b. pertussis), virus poliomyelitis typus 1 inactivatus (stamm mahoney), virus poliomyelitis typus 2 inactivatus (stamm mef-1), virus poliomyelitis typus 3 inactivatus (stamm saukett) - injektionssuspension - toxoidum diphtheriae min. 30 u.i., toxoidum tetani min. 40 u.i., toxoidum pertussis 25 µg, haemagglutininum filamentosum (b. pertussis) 25 µg, pertactinum (b. pertussis) 8 µg, virus poliomyelitis typus 1 inactivatus (stamm mahoney) 40 u.i., virus poliomyelitis typus 2 inactivatus (stamm mef-1) 8 u.i., virus poliomyelitis typus 3 inactivatus (stamm saukett) 32 u.i., aluminium 0.5 mg ut aluminii hydroxidum hydricum ad adsorptionem, natrii chloridum corresp. natrium 1.8 mg, medium 199, aqua ad iniectabile ad suspensionem pro 0.5 ml, residui: neomycini sulfas, polymyxini b sulfas, formaldehydum, polysorbatum 80. - grundimmunisierung und auffrischimpfung, gegen diphtherie, tetanus, pertussis und poliomyelitis, ab dem vollendeten 2. lebensmonat - impfstoffe

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - toxoidum diphtheriae, toxoidum tetani, toxoidum pertussis, haemagglutininum filamentosum von bordetella pertussis, pertactinum von bordetella pertussis, virus poliomyelitis typus 1 inactivatus, virus poliomyelitis typus 2 inactivatus, virus poliomyelitis typus 3 inactivatus - injektionssuspension - toxoidum diphtheriae ≥ 2 u.i., toxoidum tetani ≥ 20 u.i., toxoidum pertussis 8 µg, haemagglutininum filamentosum von bordetella pertussis 8 µg, pertactinum von bordetella pertussis 2.5 µg, virus poliomyelitis typus 1 inactivatus 40 u., virus poliomyelitis typus 2 inactivatus 8 u., virus poliomyelitis typus 3 inactivatus 32 u., natrii chloridum corresp. natrium 1.8 mg, aluminium 0.5 mg ut aluminii hydroxidum hydricum ad adsorptionem et aluminii phosphas, medium 199, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml, residui: neomycini sulfas, polymyxini b sulfas, polysorbatum 80, formaldehydum. - aktive auffrischimpfung gegen diphtherie, tetanus, pertussis und poliomyelitis, ab dem vollendeten 4. lebensjahr - impfstoffe

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - toxoidum tetani, toxoidum diphtheriae - injektionssuspension - impfstoff adsorbatum: toxoidum tetani min. 20 u. i., toxoidum diphtheriae min. 2 u. i., aluminii hydroxidum (65% al2o3), formaldehydum max. 1 µg, natrii chloridum, aqua ad iniectabilia q.s. zu der suspension 0,5 ml. - aktive immunisierung gegen diphtherie und tetanus, ab dem vollendeten 5. lebensjahr - impfstoffe

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

bavarian nordic berna gmbh - toxoidum diphtheriae, toxoidum tetani - injektionssuspension - toxoidum diphtheriae min. 30 u.i., toxoidum tetani min. 40 u.i., adjuvans: aluminium ut aluminii phosphatis liquamen, natrii chloridum, natrii acetas trihydricus, natrii carbonas, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml corresp. natrium 2.10 mg. - aktive immunisierung gegen diphtherie und tetanus, ab geburt bis zum 8. geburtstag - impfstoffe

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

novo nordisk pharma ag - insulinum aspartum - injektionssuspension - insulinum aspartum 100 u., insulinum löslich 30 % und insulinum isophanum 70 %, protamini sulfas, zink als zinci chloridum, glycerolum, natrii chloridum, natrii phosphates oder, conserv.: phenolum 1.50 mg, metacresolum 1.72 mg, wasser iniectabilia q.s. um die suspension für 1 ml. - diabetes mellitus - biotechnologika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

novo nordisk pharma ag - insulinum aspartum - injektionssuspension - insulinum aspartum 100 u., insulinum löslich 30 % und insulinum isophanum 70 %, protamini sulfas, zink als zinci chloridum, glycerolum, natrii chloridum, natrii phosphates oder, conserv.: phenolum 1.50 mg, metacresolum 1.72 mg, wasser iniectabilia q.s. um die suspension für 1 ml. - diabetes mellitus - biotechnologika